Influenza A virus hemagglutinin H5 (HA) (HA)

Hemagglutinin (HA) is the primary surface glycoprotein of the H5N1 influenza A virus and is essential for viral infectivity. It functions as a class I fusion protein that mediates two critical steps of the viral life cycle: binding to host cell surface sialic acid receptors and facilitating the fusion of the viral envelope with the host endosomal membrane (UniProt, 2024). In H5N1, the HA protein typically shows a preference for alpha-2,3-linked sialic acids, which are prevalent in avian species, but it can mutate to recognize alpha-2,6-linked receptors found in the human respiratory tract (PubMed, 2023). This receptor specificity is a major determinant of the virus's host range and pandemic potential. Because HA is the main target for neutralizing antibodies, it is the key antigen used in the development of H5N1 vaccines, such as Audenz (FDA, 2020). Therapeutic interventions targeting HA include monoclonal antibodies that bind to the conserved stem region to prevent the conformational changes required for membrane fusion (Nature, 2016). Small molecule inhibitors like Umifenovir also target the HA-mediated fusion process to inhibit viral entry (PubChem, 2024). However, the rapid evolution of the HA protein through antigenic drift poses a significant challenge for long-term vaccine efficacy and drug development (CDC, 2024). Monitoring HA mutations is crucial for pandemic preparedness and the selection of vaccine strains.

Other names

H5N1 HAHemagglutininH5 proteinSurface glycoproteinHA1/HA2

Inhibition of viral attachment to host sialic acid receptors and prevention of pH-dependent membrane fusion within the endosome.